• Corpus ID: 53392637

Association of Niacin on Phosphate Control in Advanced-Stage Chronic Kidney Disease Patients within a VA Population

  title={Association of Niacin on Phosphate Control in Advanced-Stage Chronic Kidney Disease Patients within a VA Population},
  author={Nicholas J. Burge},
Current options for lowering phosphate levels have many limitations. A novel approach for treating hyperphosphatemia is the use of niacin therapy, which has been shown to decrease serum phosphorus by inhibiting type IIb sodium-phosphate cotransporter in the gastrointestinal tract. The primary objective of this study was to compare phosphorus control in patients with advanced stages of CKD who received or did not receive niacin. Male patients aged 18 years or older at the Edward Hines, Jr. VA… 

Figures and Tables from this paper


Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.
There is definitive evidence that once-daily ERN-L treatment causes a sustained 0.13-mmol/L reduction in serum phosphorus concentrations, approximately 10% from baseline, which is unaffected by estimated GFR ranging from 30 to > or =90 ml/min per 1.73 m(2) (i.e., stages 1 through 3 chronic kidney disease).
Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients.
Niaspan effectively lowered serum phosphate levels and significantly increased HDL cholesterol in patients who were undergoing dialysis and may provide an alternative or adjunctive treatment option in dialysis patients.
Phosphate management in chronic kidney disease
  • I. Bhan
  • Medicine
    Current opinion in nephrology and hypertension
  • 2014
An improved understanding of phosphate regulation and the development of new therapeutic agents have reinvigorated a once stagnant field, but significant changes to practice cannot yet be justified.
Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients.
In incident CKD patients there is a high prevalence of out-of-target mineral and bone analytical parameters, and the currently authorized therapeutic arsenal for these patients may not be adequate to deal with the problem.
Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
This short-term study suggests that although nicotinic acid reduced hyperphosphatemia, sevelamer showed higher efficacy in controlling hyperph phosphatemia as well as the Ca-P product.
Extended Release Nicotinic Acid – A Novel Oral Agent for Phosphate Control
Oral nicotinic acid may emerge as a safe, low cost yet powerful agent for phosphorus control in dialysis patients.
Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis
Niacin and its analog effectively improved phosphorus metabolism in renal dialysis patients, however, niacin can cause flushing and niac inamide probably cause thrombocytopenia.
Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.
In patients with fasting serum phosphorus >5 mg/dl, nicotinamide effectively decreased phosphorus, increased high-density lipoprotein, and caused thrombocytopenia, and it is necessary to plan other studies for assessing the safety of the drug especially in different populations.
Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.
The daily pill burden in dialysis patients is one of the highest reported to date in any chronic disease state and associated with lower HR-QOL, and there is a modest relationship between pill burden from phosphate binders and adherence and serum phosphorus levels.
Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
The evidentiary basis for a strong, consistent, and independent association between serum levels of calcium and parathyroid hormone and the risk of death and cardiovascular events in chronic kidney disease is poor.